Saturday 17 October 2026
Export EWTX’s income statement to Excel — free account
Edgewise Therapeutics, Inc.
EWTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 55.9% and free cash flow fell 30.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
37.19
1.01
−2.64%
Follow EWTX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '17 | |
|---|---|---|---|---|---|---|---|
Current Ratio |
19.85 | 19.93 | 19.50 | 21.53 | 26.97 | 29.86 | — |
Net Debt/EBITDA |
2.69 | 2.78 | 2.61 | 4.91 | 6.54 | 7.59 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.86 | 0.81 | 0.92 | 0.78 | 0.78 | 0.85 | — |
Capex/Depreciation |
0.05 | 0.13 | 0.74 | 1,109.20 | (2.46) | (1.10) | — |
| (34.19%) | (34.40%) | (30.10%) | (21.78%) | (35.53%) | (14.21%) | — | |
| (32.29%) | (32.37%) | (28.33%) | (20.74%) | (20.56%) | (26.11%) | — | |
ROIC |
0.00% | 0.00% | (16,355.41%) | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(32.03%) | (29.02%) | (31.24%) | (19.38%) | (15.62%) | (13.61%) | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Free Cash Flow per Share |
(1.40) | (1.19) | (1.53) | (1.09) | (0.91) | (20.08) | — |
Cash per Share |
5.15 | 5.09 | 5.00 | 6.57 | 7.48 | 174.69 | — |
Shareholders Equity per Share |
5.07 | 4.97 | 5.00 | 6.47 | 7.31 | 171.58 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
5.07 | 4.97 | 5.00 | 6.47 | 7.31 | 171.58 | — |
Free Cash Flow |
(144.07) | (110.34) | (97.69) | (58.18) | (34.17) | (14.84) | — |
Working Capital |
516.02 | 451.62 | 310.23 | 340.41 | 273.25 | 125.30 | — |
Capital Expenditures |
(0.26) | (1.31) | (5.74) | (5.55) | (0.67) | (0.20) | — |
Net Current Asset Value |
513.04 | 447.88 | 305.79 | 336.61 | 272.92 | 125.30 | — |
| Other line items | |||||||
Quick Ratio |
19.37 | 19.71 | 18.98 | 21.22 | 26.69 | 29.73 | — |
Depreciation/Fixed assets |
(0.69) | (1.08) | (0.75) | 0.00 | 0.30 | 0.36 | — |
Cash ROIC |
(13.69%) | (11.87%) | (15.33%) | (8.33%) | (6.16%) | (5.80%) | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(1.40) | (1.18) | (1.44) | (0.98) | (0.89) | (19.80) | — |
Capex per Share |
0.00 | (0.01) | (0.09) | (0.10) | (0.02) | (0.27) | — |
Average Payables |
5.79 | 4.80 | 5.07 | 4.97 | 2.71 | 2.71 | — |
Average Assets |
519.71 | 413.43 | 353.57 | 326.17 | 208.18 | 65.57 | — |
Average Common Equity |
490.74 | 389.02 | 332.77 | 310.55 | 120.48 | 120.48 | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Columns are period end dates